Professor Claude M. Wischik, co-founder and Executive Chairman of TauRx Therapeutics, along with colleagues at the University of Aberdeen, has devoted nearly 30 years to investigating the structure and role of tau tangles in the development of Alzheimer’s, frontotemporal dementia (FTD) and other neurodegenerative diseases. They are the original discoverers of the composition of the tau protein pathology in Alzheimer’s.
TauRx’s second-generation tau aggregation inhibitor (TAI), LMTX®, is a novel chemical form of methylthioninium (MT). In its chloride salt form (methylene blue, or methylthioninium chloride (MTC)) it is an active moiety with a long history of use in the treatment of a variety of conditions.
LMTX® works by undoing the tangles that cause dementia, thereby slowing and even arresting memory loss. This second-generation investigational drug has improved bioavailability, tolerability and safety compared with its predecessor, rember®, which was used in Phase 2 clinical trials in Alzheimer’s.
TauRx has composition of matter patents and use patents covering the application of its TAIs for the treatment and prevention of Alzheimer’s and FTD. The company is also exploring the use of TAIs in several other neurodegenerative diseases associated with tau pathology, as well as other disorders deriving from the aggregation of other proteins in the brain, including Parkinson’s and Huntington’s.